Expression of matrix metalloproteinases 1 and 2 genes in a possible association with metastatic abilities of human pancreatic cancer cells

International Journal of Oncology

Volumn 10, Issue 3, 1997, Pages 623-628

  Jimi, Sei Ichiro ^a   Shono, Tadahisa ^a   Ono, Mayumi ^a   Kuwano, Michihiko ^a   Tanaka, Masao ^a   Lopez Otin, Carlos ^b   Kono, Akira ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSIDAD DE OVIEDO   (Spain)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

liver metastasis; matrix metalloproteinase (MMP); pancreatic cancer; plasminogen activator; tissue inhibitor of metalloproteinase (TIMP)

Indexed keywords

COLLAGENASE; GELATINASE A; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0031000850     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.3.623     Document Type: Article

References (38)

1. Saito Y, Yamamoto M and Ohashi O: The present status of pancreatic cancer registration. In: Gann Monograph on Cancer Research 43, Cancer treatment and survival site-specific registries in Japan. Japanese Cancer Association Japanese Scientific Societies Press, Tokyo pp107-117, 1995.
2. Stetler-Stevenson WG, Liotta LA and Kleiner DE Jr: Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7: 1434-1441, 1993.
3. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266, 1985.
4. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trend Genet 6: 121 -125, 1991.
5. Gress TM, Muller-Pillasch F, Lerch MM, Friess M, Buchler M and Adler G: Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 62: 407-413, 1995.
6. Ikeda Y, Ezaki M, Hayashi I, Nakayama K and Kono A: Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice. Jpn J Cancer Res 81: 987-993, 1990.
7. Yasuda D, Iguchi H, Ikeda Y, Nishimura S, Steeg PS, Misawa T, Nawata H and Kono A: Possible association of Nm23 gene expression and Ki-ras point mutations with metastatic potential in human pancreatic cancer-derived cell lines. Int J Oncol 3: 641-644, 1993.
8. Iwamura T, Katsuki T and Ide K: Establishment and characterization of a human pancreatic cancer cell line (Suit-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res 78: 54-62, 1987.
9. Nakayama Y, Kohno K, Nomura Y, Naito S, Ono M, Shimizu K, Osato K and Kuwano M: Enhanced invasive activity and decreased expression of tissue inhibitors of metalloproteinases. Clin Exp Metastasis 12: 296-304, 1994.
10. Ito K, Ryuto M, Ushiro S, Ono M, Sugenoya A, Kuraoka A, Shibata Y and Kuwano M: Expression of tissue-type plasminogen activator and its inhibitor couples with development of capillary network by human microvascular endothelial cells on Matrigel. J Cell Physiol 162: 213-224, 1995.
11. Uria JA, Ferrando AA, Velasco G, Freije JMP and Lopez-Otin C: Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 54: 2091-2094, 1994.
12. Giavazzi R, Campbell DE, Jessup JM, Cleary K and Fidler IJ: Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res 46: 1928-1933, 1986.
13. Jimi S, Ito K, Kohno K, Ono M, Kuwano M, Itagaki Y and Ishikawa H: Modulation by bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells. Biochem Biophys Res Commun 211: 476-483, 1995.
14. Abe T, Okamura K, Ono M, Kohno K, Mori T, Hori S and Kuwano M: Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis. J Clin Invest 92: 54-61, 1993.
15. Chcn WT: Membrane proteases: roles in tissue remodeling and tumor invasion. Curr Opin Cell Biol 4: 802-809, 1992.
16. Stetler-Stevenson WG, Krutzsch HC and Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374-17378, 1989.
17. Howard EW, Elizabeth CB and Michael JB: Preferential inhibition of 72- and 92- kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem 266: 13070-13075, 1991.
18. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies IMK and Liotta LA: The activation of human type IV collagenase proenzyme. J Biol Chem 264: 1353-1356, 1989.
19. Stearns ME and Wang M: Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 53: 878-883, 1993.
20. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A and Kossakowska AE: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 66: 1188-1194, 1992.
21. Montgomery AMP, Mueller BM, Reisfeld RA, Taylor SM and Declerck YA: Effect of tissue inhibitor of the metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 54: 5467-5473, 1994.
22. Apte SS, Mattei MG and Olsen BR: Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP-3 gene to chromosome 22. Genomics 19: 86-90, 1994.
23. Apte SS, Olsen BR and Murphy G: The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 270: 14313-14318, 1995.
24. Leco KJ, Khokha R, Pavloff N, Hawkes SP and Edwards DR: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269: 9352-9360, 1994.
25. Ossowski L, Clunie G, Masucci M-T and Blasi F: In vitro paracrine interaction between urokinase and its receptor. Effect on tumor cell invasion. J Cell Biol 115: 1107-1112, 1991.
26. Rømer J, Pyke C, Lund LR, Eriksen J, Kristensen P, Rønne E, Høyer-Hansen G, Danø K and Brünner N: Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 57: 553-560, 1994.
27. Ossowski L: Invasion of connective tissue by human carcinoma cell lines: Requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 52: 6754-6760, 1992.
28. Carlscn SA, Ramshaw IA and Warrington RC: Involvement of plasminogen activator production with tumor metastasis in a rat model. Cancer Res 44: 3012-3016, 1984.
29. Hasui Y, Suzumiya J, Marutsuka K, Sumiyoshi A, Hashida S and Ishikawa E: Comparative study of plasminogen activator production in cancers and normal mucosae of human urinary bladder. Cancer Res 49: 1067-1070, 1989.
30. Ramshaw IA, Badeneoch-Jones P, Grant A, Maxted M and Claudianos C: Enhanced plasminogen activator production by high metastatic variant cell lines of a rat mammary adenocarcinoma. Invasion Metast 6: 133-144, 1986.
31. Wang BS, McLoughlin GA, Richie JP and Mannick JA: Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines. Cancer Res 40: 288-292, 1980.
32. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, Danø K, Ruiter DJ and Verheijen JH: Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinasemediated matrix degradation. J Cell Biol 115: 191-199, 1991.
33. Nicolson GL, Winkelhake JL and Nussey AC: An approach to studying the cellular properties associated with metastasis: some in vitro properties of tumor variants selected in vivo for enhanced metastasis. In: Fundamental Aspects of Metastasis. Weiss L (ed.) North-Holland, Amsterdam pp291-303, 1976.
34. Taniguchi S, Iwamura T, Kitamura N, Yamanari H and Setoguchi T: Heterogeneities of attachment, chemotaxis, and protease production among clones with different metastatic potentials from a human pancreatic cancer cell line. Clin Exp Metastasis 12: 238-244, 1994.
35. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H and Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat Rep 24: 195-208, 1993.
36. Grøndahl-Hansen J, Kristensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993.
37. Pedersen H, Grøndahl-Hansen J, Francis D, østerlind K, Hansen HH, Danø K and J Brünner N: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-123, 1994.
38. Pedersen H, Brünner N, Francis D, østerlind K, Rønne E, Hansen HH, Danø K and Grøndahl-Hansen J: Prognostic impact of urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675, 1994.